• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • ALK
    1 Drug classified under this drug class


    All the Drug Class Drugs

    LORVIQUA
    Pfizer
    RX
    partial basket chart
    LORVIQUA

    ALK, Tyrosine Kinase Inhibitor. Lorlatinib 25 mg, 100 mg.
    F.C. TABS.: 90, 120×25mg, 30×100mg. 100 mg×1/d orally, with/without food, at the same time each day, until dis. progress. or unacceptab. toxic.
    Swallow tablets whole. If a dose is missed, then the missed dose should be taken, unless the next dose is due within 4 hrs. If vomit. occurs after lorlatinib cont. with the next scheduled dose. 2 doses should not be taken at the same time to make up for a missed dose. See lit.
    Tmt. of pts. with anaplast. lymphom. kinase (ALK)-positive metast. NSCLC whose dis. has progressed on;
    crizotinib and at least one other ALK inhib. for metast. dis.;
    alectinib as the first ALK inhib. for metast. dis.;
    ceritinib as the first ALK inhib. for metast. dis.
    C/I: Pts. taking strong CYP3A induc., due to the potential for serious hepatotox. Hypers.

    CLOSE